Immune landscape in Burkitt lymphoma reveals M2-macrophage polarization and correlation between PD-L1 expression and non-canonical EBV latency program.

Autor: Granai M; 1Department of Medical Biotechnology, University of Siena, Siena, Italy.; 2University Hospital of Tübingen, Institute of Pathology, Tübingen, Germany., Mundo L; 1Department of Medical Biotechnology, University of Siena, Siena, Italy., Akarca AU; 3Department of Pathology, University College London, London, UK., Siciliano MC; 1Department of Medical Biotechnology, University of Siena, Siena, Italy., Rizvi H; 4Department of Cellular Pathology, Barts Health NHS Trust, London, UK., Mancini V; 1Department of Medical Biotechnology, University of Siena, Siena, Italy., Onyango N; 5Department of Clinical Medicine and Therapeutics, University of Nairobi, Nairobi, Kenya., Nyagol J; 6Department of Human Pathology, University of Nairobi, Nairobi, Kenya., Abinya NO; 5Department of Clinical Medicine and Therapeutics, University of Nairobi, Nairobi, Kenya., Maha I; 7South Egypt Cancer Institute, Assiut University, Assiut, Egypt., Margielewska S; 8Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK and Durham University, Durham, UK., Wi W; 8Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK and Durham University, Durham, UK., Bibas M; 9Clinical Department, National Institute for Infectious Diseases 'Lazzaro Spallanzani' I.R.C.C.S, Rome, Italy., Piccaluga PP; 10Department of Experimental, Diagnostic, and Specialty Medicine Bologna University Medical School, S. Orsola Malpighi Hospital, Bologna and Euro-Mediterranean Institute of Science and Technology (IEMEST), Palermo, Italy., Quintanilla-Martinez L; 2University Hospital of Tübingen, Institute of Pathology, Tübingen, Germany., Fend F; 2University Hospital of Tübingen, Institute of Pathology, Tübingen, Germany., Lazzi S; 1Department of Medical Biotechnology, University of Siena, Siena, Italy., Leoncini L; 1Department of Medical Biotechnology, University of Siena, Siena, Italy., Marafioti T; 11Department of Cellular Pathology, University College Hospital, London, London UK.; 3Department of Pathology, University College London, London, UK.
Jazyk: angličtina
Zdroj: Infectious agents and cancer [Infect Agent Cancer] 2020 May 06; Vol. 15, pp. 28. Date of Electronic Publication: 2020 May 06 (Print Publication: 2020).
DOI: 10.1186/s13027-020-00292-w
Abstrakt: Background: The Tumor Microenviroment (TME) is a complex milieu that is increasingly recognized as a key factor in multiple stages of disease progression and responses to therapy as well as escape from immune surveillance. However, the precise contribution of specific immune effector and immune suppressor components of the TME in Burkitt lymphoma (BL) remains poorly understood.
Methods: In this paper, we applied the computational algorithm CIBERSORT to Gene Expression Profiling (GEP) datasets of 40 BL samples to draw a map of immune and stromal components of TME. Furthermore, by multiple immunohistochemistry (IHC) and multispectral immunofluorescence (IF), we investigated the TME of additional series of 40 BL cases to evaluate the role of the Programmed Death-1 and Programmed Death Ligand-1 (PD-1/PD-L1) immune checkpoint axis.
Results: Our results indicate that M2 polarized macrophages are the most prominent TME component in BL. In addition, we investigated the correlation between PD-L1 and latent membrane protein-2A (LMP2A) expression on tumour cells, highlighting a subgroup of BL cases characterized by a non-canonical latency program of EBV with an activated PD-L1 pathway.
Conclusion: In conclusion, our study analysed the TME in BL and identified a tolerogenic immune signature highlighting new potential therapeutic targets.
Competing Interests: Competing interestsThe authors declare that they have no competing interests.
(© The Author(s) 2020.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje